GlobeNewswire Inc | Jan 5, 2022 08:00AM EST

January 05, 2022

AUSTIN, Texas, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Aspira Womens Health Inc. (Nasdaq: AWH), a bioanalytical-based womens health company, today announced that Minh Merchant will join the Company as General Counsel and Corporate Secretary, effective Jan. 4, 2022. In this role, Ms. Merchant will lead the Companys legal, compliance, and enterprise risk management functions, reporting to Valerie Palmieri, CEO.

Ms. Merchant is a seasoned executive with deep healthcare experience, which includes companies spanning the market cap spectrum. From her contributions at a Fortune 5 public healthcare company, where she provided steady guidance on complex issues, to her strategic counsel at a nimble pre-IPO start up where she oversaw several transactions and financings just prior to its $375 million merger with a public company, Ms. Merchant has provided legal counsel and regulatory oversight on all aspects of corporate matters. Prior to joining Aspira, Ms. Merchant served as General Counsel, Corporate Secretary and Corporate Compliance Officer at Genome Medical Inc., a private telegenomics company. Prior to that, she served as Associate General Counsel, Global Director of Litigation & Human Resources at Myriad Genetics where she provided legal and strategic guidance on all matters of healthcare regulations, compliance, privacy commercial relationships, federal and state regulations and clinical trials. Ms. Merchant began her corporate career at McKesson Corporation, a Fortune 5 company and the largest pharmaceutical distributor in the nation, where she served Chief Counsel after one decade in private legal practice. Ms. Merchant began her career in law after graduating from UCLA School of Law where she was the Joseph Drown Fellow. Ms. Merchant has served as President of the Vietnamese American Bar Association of Northern California, and was the inaugural co-chair of the National Conference of Vietnamese American Attorneys in 2008.

It is with great pleasure that we warmly welcome Minh to our senior management team. She is an extraordinarily talented and experienced executive with deep knowledge of the healthcare industry, said Valerie Palmieri, Chief Executive Officer of Aspira. With her business acumen and strategic insights, we look forward to her many contributions in the coming months and years.

Ms. Merchant added, I am very excited to join this executive team, with its core focus and singular commitment to improving the lives of women globally. The teams data-driven approach to providing solutions combined with its cutting-edge portfolio of gynecologic health products truly is a standout approach, and I look forward to being part of this exciting journey of transforming womens health.

About Aspira Womens Health Inc.Aspira Womens Health Inc. is transforming womens health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management, and improve gynecologic health outcomes for women. Aspira Womens Health is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis. OVA1plusTM combines our FDA-cleared products, OVA1 and OVERA, to detect risk of ovarian malignancy in women with adnexal masses. Aspira GenetiXTMtesting offers both targeted and comprehensive genetic testing options with a gynecologic focus. With over 10 years of expertise in ovarian cancer risk assessment, Aspira Womens Health is working to deliver a portfolio of pelvic mass products over a patients lifetime with our cutting-edge research. The next generation of products in development include OVAWatchTMand EndoCheckTM. To improve patient accessibility, Aspira Womens Health has recently launched our Aspira Synergy technology transfer platform to empower health systems, academics, regional labs, and physician group labs to conduct genetic and specialty tests in-house. Visit our website for more information at www.aspirawh.com.

Forward-Looking StatementsThis press release contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995, including statements regarding the expected use of Aspira Synergy Genetics by Axia Womens Health physicians and the expected launch of Aspira Synergy specialty tests. These statements involve a number of risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements. Words such as may, expects, intends, anticipates, believes, estimates, plans, seeks, could, should, continue, will, potential, projects and similar expressions are intended to identify forward-looking statements. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties, and assumptions, including the risks and uncertainties described in the section entitled Risk Factors in Aspira Womens Healths Annual Report on Form 10-K for the year ended December 31, 2020. The events and circumstances reflected in Aspira Womens Healths forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Aspira Womens Health expressly disclaims any obligation to update, amend or clarify any forward-looking statements to reflect events, new information or circumstances occurring after the date of this press release, except as required by law.

Investor Relations Contact:Ashley R. Robinson LifeSci Advisors, LLC Tel 617-430-7577Arr@lifesciadvisors.com